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ABSTRACT 
 
 
Prevention of Spontaneous Tumors by Pharmacological Inhibition of the Epidermal Growth 
Factor Receptor 
 
 
Jared Hart Eichner 
Department of Veterinary Medicine & Biomedical Sciences 
Texas A&M University 
 
 
Research Advisor: Dr. David W. Threadgill 
Department of Veterinary Pathobiology 
Department of Molecular and Cellular Medicine 
Texas A&M University  
 
 
The epidermal growth factor receptor (EGFR) is a ligand-activated tyrosine kinase 
receptor that is often overexpressed in cancers and plays a significant role in cell proliferation 
and inhibition of apoptosis. Mouse model studies have demonstrated the ability of EGFR 
inhibition to hinder spontaneous colorectal cancer occurrence by 50-80% when EGFR inhibition 
is induced before the establishment of tumors.1 The success rates reported in human clinical 
trials differ from mouse model studies, with a 15% success rate among colorectal cancer patients 
receiving anti-EGFR treatment.2 Timing of treatment is the major difference between 
animal/mouse trials and human therapeutic treatment of end-stage cancers. In our study, it was 
hypothesized that earlier preventative doses of the AG1478 chemotherapy inhibitor would 
reduce the frequency of spontaneous tumor occurrence in a preventative, rather than therapeutic, 
manner in a murine population. This current study provides additional specificity and 
histopathological analysis of the spontaneous tumor occurrence in a large murine sample of four 
genetically distinct wild-type strain mice to better simulate a variable human population. Such 
specificity includes, but is not limited to, the number, type and severity of the tumors that did 
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occur and whether the concentration of the drug is correlated to a reduction in tumor occurrence. 
Such information will broaden the discussion of EGFR’s role in tumor treatment. 
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NOMENCLATURE  
 
AG1478    EGFR kinase inhibitor chemotherapy used in this murine experiment 
A/J      One of four strains of mice studied in this project 
ApcMin/+       Heterozygous for the hyperactive oncogenic allele leading to colorectal cancer  
BALB/cJ    One of four strains of mice studied in this project 
C57BL/6J      One of four strains of mice studied in this project 
EGF     Epidermal growth factor      
EGFR     Epidermal growth factor receptor (protein)   
EGFR-TKI         Epidermal growth factor receptor tyrosine kinase inhibitor 
Egfrwa2/wa2    Homozygous for the hypomorphic allele of EGFR 
FVB/NJ     One of four strains of mice studied in this project 
IC50   Half maximal inhibitory concentration measures a substance’s effectiveness to   
inhibit a specific biological or biochemical process 
 Mitotic index      Ratio of the number of cells undergoing mitosis to the total number of cells  
 µm                Micrometer (1x10-6 meters) 
 Murine Mouse model (study) 
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CHAPTER 1 
INTRODUCTION 
 
The ability of EGFR inhibition to hinder spontaneous tumor occurrence has been 
demonstrated by multiple studies which have expanded the body of knowledge about the 
efficacy of such treatment.1,3 Previous research shows a strong, positive correlation between 
EGFR over activity and the occurrence of several types of cancers prevalent in humans, 
including colorectal cancer,4 pulmonary adenocarcinoma,5 head and neck cancer,6 soft tissue 
sarcoma,7 prostate cancer,8 glioblastoma,9 and breast cancer.10 
However, in human subjects, EGFR inhibition is generally used only in terminally ill 
cancer patients, due to known, and possible unknown, long-term consequences of EGFR 
inhibition. As a result, EGFR inhibition as a preventative and therapeutic chemotherapy have 
often been studied through murine genetic model experiments. Mouse trials have shown that 
EGFR inhibition can hinder spontaneous tumor occurrence by 50-80% when EGFR is inhibited 
before the establishment of tumors.1 By contrast, later human therapeutic treatment has shown a 
15% success rate among colorectal cancer patients receiving anti-EGFR treatment for end-stage 
cancers.2 In our study, the mice receive preventative doses of the chemotherapy inhibitor 
AG1478 at two months of age. 
Mice with hypomorphic Egfrwa2/wa2, or hyperactive oncogenic ApcMin/+ alleles, are were 
previously the subjects in genetic models to study anti-tumor capabilities of EGFR inhibition and 
have shown significant results. The hypomorphic Egfrwa2/wa2 allele, for example, showed a 90% 
reduction in murine colorectal cancer,3 while an 80% reduction in murine polyps was seen in an 
ApcMin/+ model.1 The preventative opportunities of AG1478 chemotherapy are the subject of this 
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study, using four genetically-distinct strains of wild-type mice which receive AG1478 drug 
administration (0mg control, 5mg, 50mg, or 144mg). Wild-type A/J, BALB/cJ, C57BL/6J, 
FVB/NJ mice are used in this study because expected frequencies of spontaneous tumor 
occurrence allowed for the determination of the efficacy of AG1478.  
Objectives 
As there are numerous gaps in the knowledge base concerning EGFR inhibition, this 
study uses histopathological analysis of four genetically-distinct wild-type strains of mice 
predisposed to cancer to study tumor development and growth by assessing the extent to which, 
if any, factors such as sex, genetics, and dosage of medication impact tumor development and 
growth. We hypothesize that the positive correlation between EGFR inhibition and the 
occurrence of cancer will result in the treatment group of mice having a lower occurrence of 
cancer, whether such drug administration is at the therapeutic or subtherapeutic dosage level, 
when compared to the control group of mice that do not receive the drug AG1478 chemotherapy. 
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CHAPTER II 
METHODS 
 
This study utilized 640 total mice, evenly divided among four genetically-distinct strains 
predisposed to certain cancers, as shown in Table 1. Table 2 shows the expected spontaneous 
tumor occurrence of each genetically distinct mouse strain. 
Table 1. Number of mice in each cohort by genetic strain, sex and dosage level. 
640 total mice 
160 per genetically-distinct strain A/J, BALB/cJ, C57BL/6J, FVB/NJ 
80 per sex per strain (male or female) of each of A/J, BALB/cJ, C57BL/6J, FVB/NJ 
20 per dosage level per sex per strain (dosages 0 mg/kg control, 5 mg/kg subtherapeutic, 50 
mg/kg subtherapeutic, & 144 mg/kg therapeutic) 
 
Table 2. Expected spontaneous tumor occurrence of each genetically distinct mouse strain [from 
the Jackson Lab MGI (mouse genome informatics) website] 
(http://www.informatics.jax.org/phenotypes.shtml). 
 
Expected Spontaneous Tumor Occurrence  
A/J BALB/cJ C57BL/6J FVB/NJ 
● Mammary gland 
(28% of females) 
● Lung (90% by 18 
months of age) 
● Muscle/soft tissue 
(79% after 20 
months of age) 
● Mammary gland 
(30% by 7 months 
of age) 
● Leukocyte 
leukemia (35% by 
7 months of age) 
● Lung (50% by 8 
months) 
● Lymphoma (75%) 
● Liver (30%) 
● Pituitary (83% 
after 20 months 
of age) 
● Leukocyte (22-
51% of males, 
10% of females) 
● Lymphoma 
(31% in females 
after 12 months) 
● Lung (29% of 
males, 17% of 
females - both 
genders by 20 
months of age) 
● Mammary 
gland (40% of 
virgin females 
by 13 months 
of age) 
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Wild-type A/J, BALB/cJ, C57BL/6J, and FVB/NJ mice were used in this study because 
the known frequencies of spontaneous tumor occurrence could be used to determine the efficacy 
of AG1478. The spontaneous tumor predispositions of the four strains of mice to various cancers 
are shown in Table 2 above. Chi-squared and Pearson's tests were used to determine the 
statistical significance and efficacy of AG1478 with respect to pulmonary adenomas and soft 
tissue sarcomas at varying doses in the A/J strain, as shown in Figures 6 and Table 4. Such 
information is not available at this time for other tissue types with respect to the A/J strain, and 
any tissue types with respect to the BALB/cJ, C57BL/6J, and FVB/NJ strains. 
Administration of Medication 
In addition to an untreated control group, other groups of mice received alternative doses 
of the AG1478 drug, which blocks ATP from binding at the kinase domain of the receptor. Such 
doses were incorporated into the mouse chow. AG1478 is very specific to EGFR (IC50 = 3 nM), 
and we therefore hypothesized that a subtherapeutic dosage might yield significant results due to 
the minimal amount of drug necessary to inhibit EGFR. Each group of 20 mice, distinguished by 
sex for each genetically-distinct strain, received drug administration (0mg control, 5mg, 50mg, 
or 144mg) starting at two months of age and ending at 18 months of age. Actual medication 
dosage for an individual mouse might have varied from the group average, as a result of the mice 
being fed from a common, abundant food supply per cage housing 4-5 mice and individualized 
altered feeding behavior due to possible factors such as the taste and neurologic effects of the 
drug. The calorimetry chamber machine measured the average amount of food eaten, categorized 
by the four strains of mice.  
The mice were fed Research Diets, D12079B formula, [high fat (21% gm% and 41 
kcal%), high carbohydrate (50% gm% and 43 kcal%) and low protein diet (20% gm% and 17& 
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kcal%)], referred to as a ‘Western’ diet, to better simulate a common diet of the American 
population.  
Euthanasia and Necropsy 
The majority of mice were euthanized by carbon dioxide inhalation after receiving 16 
months of AG1478, some mice were found deceased and their tissue was discarded, and other 
mice were euthanized by carbon dioxide inhalation and necropsied early due to aggressive 
tumors that visibly inhibited their quality of life. Tissue was harvested post-necropsy. 
Preliminary analysis of this tissue provided the initial assessment of cancer and hyperplasia 
occurrence, with measurement of weight, size and tissue coloration to assess potential 
abnormalities and visual examination. 
Tissue Handling 
 At necropsy, all tissue was organized and placed in histology cassettes. The cassettes 
were placed into containers of formalin where they were fixed for 48 hours before being 
transported to the Texas A&M Department of Veterinary Pathobiology Histology Laboratory for 
processing. In this lab, the tissue was processed, including the absorption and homogenous 
infusion of paraffin wax into the tissue in order to allow for easily hydrated tissue that could be 
evenly sectioned into 5µm thick segments, without tearing. The lung, lymph node, and spleen 
tissue were then individually placed in a metal mold, and liquid paraffin wax was poured over 
the tissue to orient it in an optimal position for sectioning. Spleen and kidney tissue required an 
additional step of cutting the organ in half with a scalpel, in order to produce a full view of the 
inside of the organ without wasting tissue due to excess sectioning. The embedded tissue was 
cooled, trimmed, sectioned via microtome to a thickness of 5 µm, placed on the surface of a hot 
water bath at 42.0 degrees Celsius, placed onto a glass slide, and dried overnight. 
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Slide Preparation 
The slides underwent a staining process which first involved the chemical removal of 
excess paraffin wax by xylene, acid wash (1% HCl and 99% ethanol), and various concentrations 
of ethanol (ranging from 70% to 100%). The remaining tissue was stained first with 
hematoxylin, which stains the nucleus blue, and next with eosin, which stains the cytoplasm red, 
and then viewed under a compound microscope. 
Histopathological Analysis 
Slide production sequence was determined by two criteria, with the first being those 
mouse line strains which are most predisposed to developing adenomas and are thus most likely 
to be affected by EGFR inhibition, such as BALB/cJ.  The second criteria for earlier slide 
production was any tissue that was visually noted as appearing abnormal in a way that indicated 
it was potentially cancerous.  
This initial assessment determined the sequence in which such stained tissue was 
submitted to further examination under microscope by Dr. Amie Perry, a veterinary anatomic 
pathologist (DACVP 2015) who is pursuing a PhD in veterinary pathobiology at Texas A&M - 
College Station, Texas. Dr. Perry identified abnormalities in the type of tumor, aggressiveness of 
growth (using a Mitotic index methodology), and presumed direction of growth of any cancerous 
tissue.   
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CHAPTER III 
RESULTS 
 
Histological examination of tissue, including lungs and various soft tissue masses, was 
performed to quantify and categorize tumor incidences. Tumor tissue was evaluated both grossly 
by visual inspection, and histopathologically using H&E staining and a compound microscope, 
to draw conclusions on the severity, tissue sensitivity, timing, sex preference, and strain 
preference of the chemotherapy at different dosages. Figures 1 - 5 below show examples of such 
abnormal tissue. Results showed that subject sex and medication dosage impacted tumor 
development and growth in the subject wild mice, as detailed in Tables 3 and 4, as well as Figure 
6. 
 
Figure 1. Lung of A/J mouse (50 mg/kg dose). Pulmonary adenoma, 1mm diameter (20X 
magnification) 50 mg/kg dose. 
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Figure 2. Hindlimb of A/J mouse (50 mg/kg dose). Soft tissue sarcoma invading muscle (100X 
magnification) 50 mg/kg dose. This slide shows the migration of bone marrow cells invading the 
hindlimb muscle. This reveals the severity of this sarcoma and the likelihood of metastasis for 
similar cancers in this mouse.   
 
 
 
Figure 3. Hindlimb of A/J mouse (0 mg/kg). Soft tissue sarcoma with high Mitotic index. Red 
circles indicate mitotic cellular divisions (400X magnification) 0 mg/kg dose This slide shows a 
high number of cells (seven) in the “mitosis” phase of the cell cycle. This Mitotic index indicates 
that these cells are proliferating more continuously than is typical and thus are likely cancerous.  
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Figure 4. Evidence of hyperplasia (abnormally large growth of white pulp) in splenic tissue of a 
C57BL/6J mouse at 13 months (5X magnification).  
 
 
Figure 5. Evidence of white pulp hypoplasia in splenic tissue of 13-month old C57BL/6J mouse 
at 5X magnification. (Note, to better visualize this evidence, the brightness and contrast were 
adjusted slightly, on both the microscope and computer image, after the image was captured.) 
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Table 3. Number of A/J male and female mice that survived until the end of the 16-month study 
(mice were 18 months of age).  
 
Strain Gender 
Control  
pulmonary  
adenoma 
occurrence 
5 mg 
adenoma 
occurrence 
50 mg 
adenoma 
occurrence 
144 mg 
adenoma 
occurrence 
A/J Female 15 12 12 16 
A/J Male 14 16 17 16 
 
 
 
Figure 6. The frequency of A/J pulmonary adenomas of two cohorts (A/J male and A/J female) 
necropsied at 18 months of age. The significance bar (p=0.0443 with 95% certainty) indicates 
that the 144 mg/kg female A/J cohort had a statistically significant reduction in the frequency of 
pulmonary adenomas, but the male A/J cohort did not.  
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Table 4. The frequency percentages of A/J soft tissue sarcomas of two cohorts (A/J male and A/J 
female). The data includes A/J mice necropsied at 18 months of age. Using Chi-squared and 
Pearson’s tests, it was determined that neither the therapeutic nor subtherapeutic doses of 
AG1478 to the A/J population resulted in a statistically significant reduction of the frequency of 
soft tissue sarcomas. An inverse relationship between AG1478 drug concentration and 
spontaneous soft tissue sarcomas was more prevalent in the female A/J cohort, however, a 
statistically significant reduction was not observed in either cohort. 
 
Strain Sex 
Tumor  
Type 
Control  
Frequency 
5 mg 
Frequency 
50 mg 
Frequency 
144 mg 
Frequency 
A/J Female Adenoma 26.3% 22.2% 26.3% 17.6% 
A/J Male Adenoma 18.8% 11.1% 5.9% 21.1% 
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CHAPTER IV 
CONCLUSION 
 
Preliminary results support the hypothesis that subject sex and medication dosage will 
impact tumor development and growth arising from EGFR overexpression in wild mice, under 
certain circumstances. Specifically, outcomes for the female A/J mice, but not for the male A/J 
mice, show a significant reduction in adenomas, but only for the highest medication dose group 
(p=0.0443 with 95% certainty). As histopathological analysis is not complete at this time and has 
only been done on spleen and lung tissue from approximately 200 (BALB/cJ + A/J) of the 640 
mice, our conclusions may change as we analyze additional tissue samples.  
It was hypothesized that long term exposure of preventative subtherapeutic doses of 
either 5mg or 50mg of AG1478 would reduce the frequency of spontaneous tumor occurrence in 
a preventative, rather than therapeutic, manner. However, Chi-squared and Pearson's tests were 
used to determine that such subtherapeutic doses did not show statistical significance and 
efficacy of AG1478 with respect to reduction of pulmonary adenomas and soft tissue sarcomas 
in the A/J strain. At this time, we are unable to draw a conclusion as to whether the 
subtherapeutic doses were able to significantly reduce the occurrence of tumor formation in the 
remainder of the wild-type murine population. 
As histopathological analysis is not complete on the BALB/cJ, C57BL/6J and FVB/NJ 
mice, no conclusions on such strains have been drawn to date from this study. 
One reason why the A/J female cohort might be more responsive to EGFR inhibition than 
was the male cohort is hormonal (estrogen, progesterone) differences between murine males and 
females, which is also observed in human populations/studies.11 These hormones lead to cellular 
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proliferation through a mechanism known as “EGFR cross talking”.12 The pulmonary adenomas 
observed in the A/J population depend on EGFR to elicit uncontrolled cellular proliferation, 
since the inhibition of EGFR in this population resulted in statistically significant reduction. 
There are many possible reasons for the lack of statistically significant reduction in the frequency 
of soft tissue sarcomas in the A/J population. One possible reason is that the soft tissue sarcomas 
may have been independent of the EGFR activation process. Therefore, these soft tissue 
adenomas would depend on alternate pathways (such as insulin-like growth factor or MAPK 
proliferation cascades) rather than the EGFR-TK proliferation cascade. Another possible reason 
is that these soft tissue sarcomas bypassed the EGFR protein/ligand activation yet found other 
mechanisms of activating the EGFR proliferation cascade downstream of the receptor. These 
hypotheses could be answered using qPCR analysis at a later date. 
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